Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 7/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7379081 | 1.00 | PLAU (0.75) | PLAUALDH1A1HTTTSHRKDM4E | |
| SCHEMBL6434427 | 0.97 | PLAU (0.74) | PLAUALDH1A1HTTTSHRKDM4E | |
| SCHEMBL7375712 | 0.84 | PLAU (0.71) | PLAUALDH1A1HTTTSHRKDM4E | |
| SCHEMBL6434405 | 0.84 | PLAU (0.71) | PLAUALDH1A1HTTTSHRKDM4E | |
| Hydrochloric Acid SCHEMBL6435890 | 0.83 | PLAU (0.70) | PLAUALDH1A1HTTTSHRKDM4E | |
| SCHEMBL6437779 | 0.82 | PLAU (0.57) | PLAUTSHRRECQLMEN1KMT2A | |
| SCHEMBL6433727 | 0.82 | PLAU (0.57) | PLAUTSHRRECQLMEN1KMT2A | |
| SCHEMBL6434295 | 0.81 | PLAU (0.70) | PLAUTSHRKDM4EHSD17B10RECQL | |
| SCHEMBL6433224 | 0.80 | PLAU (0.75) | PLAUTSHRRECQL | |
| Hydrochloric Acid SCHEMBL6434259 | 0.80 | PLAU (0.69) | PLAUTSHRKDM4EHSD17B10RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885ALDH1A1 2641/4885HTT 3828/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885ALDH1A1 2641/4885HTT 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.